LCM
STML

Laurion Capital Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Laurion Capital Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-100,000
Closed -$1.04M – 1353
2019
Q3 		$1.04M Buy
+100,000
New +$1.31M 0.01% 634

Other funds holding STML

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Laurion Capital Management's STML Position: Q4 2019 in Review

Laurion Capital Management sold out of Stemline Therapeutics, Inc. (STML) in Q4 2019, closing a stake of 100,000 shares — an estimated $1.04M sold.

Laurion Capital Management first reported a position in STML in Q3 2019 and held it in 1 quarter. The position peaked at $1.04M in Q3 2019. 99 funds tracked by Wall St. Rank hold STML as of Q4 2019.

  • Laurion Capital Management reported no remaining Stemline Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • Laurion Capital Management sold 100,000 Stemline Therapeutics, Inc. shares in Q4 2019, an estimated $1.04M.
  • Laurion Capital Management first reported a position in Stemline Therapeutics, Inc. in Q3 2019 and held it in 1 quarter.
  • Laurion Capital Management's Stemline Therapeutics, Inc. position peaked at $1.04M in Q3 2019.
  • 99 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2019.

Based on Laurion Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.